What is your strategy for breakthrough chemotherapy induced N&V in patients receiving highly emetogenic chemotherapy and already received a NK-1 antagonist, 5-HT3 antagonist, dexamethasone, and olanzapine?   


Answer from: Medical Oncologist at Community Practice

Answer from: at Community Practice

Answer from: at Community Practice